The Board of Directors of the Company have approved the Audited Financial Results for the Quarter and Year ended March 31st 2025 at their meeting held on May 23, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Pharmaids Pharmaceuticals' board, at its May 23, 2025 meeting, approved audited financial results for Q4 and FY25. Statutory auditors M/s PPKG & Co issued an unmodified (clean) opinion on both standalone and consolidated results. On a consolidated basis, revenue from operations rose about 29% YoY to Rs. 1,944.74 lacs (FY24: Rs. 1,511.21 lacs), but the net loss widened to Rs. 1,350.51 lacs from Rs. 1,184.31 lacs, with EPS of Rs. (3.05). Standalone numbers show a similar picture — revenue jumped from Rs. 2.78 lacs to Rs. 234.09 lacs, but loss for the year deteriorated to Rs. 727.92 lacs. Operating cash flows remained heavily negative (standalone Rs. -772 lacs, consolidated Rs. -1,399 lacs), and long-term borrowings on a consolidated basis surged from Rs. 358.54 lacs to Rs. 3,018.35 lacs.
Despite a clean audit report and revenue traction, deepening losses, negative operating cash flow, and a sharp jump in borrowings are red flags. Shareholders should view this as a loss-making, cash-burning company whose stock price may stay under pressure unless losses narrow meaningfully.